Highlights Europe & Asia (March 3 & 4) - IASLC 2021 TTLC Meeting

#TTLC21

Get Tickets!

Europe Highlights (CET)

Asia Highlights (JST)

March 3

13:30 ‐ 14:40 CET	Targeted Therapies - EGFR Welcome Introduction - Giorgio Scagliotti, Italy EGFR Combinations (MET, Chemo, VEGF, Small Cell) - Helena Yu, USA EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase - Collin Blakely, USA EGFR Exon 20 Insertions: Novel TKIs, Amivantamab and Other Treatment Options - Zosia Piotrowska, USA Persister Biology - Christine Lovly, USA Live Panel Discussion - Luis Paz-Ares, USA, Noemi Reguiart, Spain, Alessandro Curioni, Switzerland, Jordi Remon, Spain, Simon Ekman, Sweden
14:40 ‐ 15:40 CET	Targeted Therapies - ALK/ ROS New Studies of Approved Agents: Crizotinib, Ceritinib, Alectinib, Lorlatinib, Ensartinib - New Data and Resistance Mechanisms - Ignatius (Sai-Hong) Ou, USA New Agents Not Yet Approved: Repotectinib, DS6051b - Jessica Lin, USA Combinations: VEGF, Trametinib, CDK4/6, mTOR - Shirish Gadgeel, USA Continuing TKI Beyond Progression (All Drivers) - Ross Camidge, USA Live Panel Discussion - Martin Reck, Germany, Joachim Aerts, Netherlands, Federico Cappuzzo, Italy, Laura Mezquita, Spain

March 4

13:30 - 14:30 CET	Targeted Therapies - All The Others MET - Rebecca Heist, USA RET Fusion-Positive Lung Cancers - Alex Drilon, USA BRAF - Ibiayi Dagogo-Jack, USA HER2, NTRK, NRG1 "Too Many Topics for a Pun" - Stephen Liu, USA Live Panel Discussion - Enriqueta Felip, Spain, Sara Pilotto, Italy, Celine Mascaux, France, Christian Grohe, Germany, AnneMarie Dingemans, Netherlands
14:30 - 15:30 CET	KRAS and Immunotherapy Sotorasib for KRAS G12C - Bob Li, USA Effect of Co-Mutations - John Heymach, USA Personalized Cancer Vaccines - Justin Gainor, USA Aiming the Immune System at Mutation-driven Tumors - Charu Aggarwal, USA Live Panel Discussion - Egbert Smit, Netherlands, Silvia Novello, Italy, Sanjay Popat, UK, Dario Sangiolo, Italy, Nicolas Girard, France

March 3

18:00 ‐ 19:10 JST	Targeted Therapies EGFR/ ALK/ MET Welcome Introduction - Tetsuya Mitsudomi, Japan EGFR Exon 20 Insetions: Novel TKIs, Amivantamab and Other Treatment Options - Zosia Piotrowska, USA Persister Biology - Christine Lovly, USA New Studies of Approved Agents: Crizotinib, Ceritinib, Alectinib, Lorlatinib, Ensartinib - New Data and Resistance Mechanisms - Ignatius (Sai-Hong) Ou, USA MET - Rebecca Heist, USA Live Panel Discussion - Caicun Zhou, China, Jianchun Duan, China, Satoru Miura, Japan, Se-hoon Lee, Republic of Korea, Junko Tanizaki, Japan
19:10 ‐ 20:10 JST	Targeted Therapies RET/ HER2/ NRG/ NTRK/ KRAS RET Fusion-Positive Lung Cancers - Alex Drilon, USA HER2, NTRK, NRG1 "Too Many Topics for a Pun" - Stephen Liu, USA Sotorasib for KRAS G12C - Bob Li, USA KRAS G12C Inhibitor Combinations - Gregory Riely, USA Live Panel Discussion - James Yang, Taiwan, Shengxiang Ren, China, Masayuki Takeda, Japan, Jin Kang, China, Herbert Loong, Hong Kong

March 4

18:00 - 19:00 JST	The Future of Immunotherapy Immunotherapy Combos: LAG-3, TIM-3, TIGIT, OX-40 - Rachel Sanborn, USA Immunotherapy Combinations CTLA-4, 41BB, ICOS - Jarushka Naidoo, Ireland Personalized Cancer Vaccines - Justin Gainor, USA Aiming the Immune System at Mutation-driven Tumors - Charu Aggarwal, USA Live Panel Discussion -Thanyanan Reungwetwattana, Thailand, Chia-Chi Lin, Taiwan, Yosuke Togashi, Japan, Hee Kyung Ahn, Republic of Korea
19:00 - 20:00 JST	SCLC/ Perioperative/ Antibody Drug Conjugates New Therapeutic Targets for SCLC - Charles Rudin, USA Adjuvant Immunotherapy and Chemo-Immunotherapy: Phase 2 Results and Ongoing Trials - Patrick Forde, USA Neoadjuvant and Adjuvant TKI Trials - Jamie Chaft, USA Antibody Drug Conjugates for HER2 and HER3 - Pasi Janne, USA Live Panel Discussion - Keunchil Park, Republic of Korea, Hye Ryun Kim, Republic of Korea, Yongsheng Wang, China, Yasushi Goto, Japan, Shun Lu, China

February 17

February 18

February 19

February 20

15:45 - 16:45 EST	Early Career/ Young Investigator Session (by invitation only) View Presentations Academic Opportunities – Suresh Ramalingam, USA Industry Opportunities – Leora Horn, USA FDA and Regulatory Opportunities – Harpreet Singh, USA Private Practice Opportunities – Edward Kim, USA Basic Science Opportunities – John Minna, USA Cancer Therapy Evaluation Program (CTEP) Externship Fellow Program, NCI – Shakun Malik, USA
17:00 - 18:00 EST	Welcome & Opening Keynote View Presentations Opening Remarks Cell Free DNA – Max Diehn, USA Live Panel Discussion
18:10 - 19:10 EST	Industry Symposium

13:30 - 14:30 EST	Targeted Therapies EGFR View Presentations EGFR + MET, EGFR + Chemo, EGFR + VEGF, SCLC Other EGFR Combo’s: MEK, Aurora K, C797S Exon 20 and Amivantimab Persister Biology Talk (All Drivers)
14:40 - 15:40 EST	Targeted Therapies ALK & ROS View Presentations New Studies of Approved Agents: Crizotinib, Ceritinib, Alectinib, Lorlatinib, Ensartinib – New Data and Resistance Mechanisms; Brigatinib New Agents Not Yet Approved: Repotectinib, DS6051b, TPX-0131 Combinations: VEGF, Trametinib, CDK4/6, mTOR Continuing TKI Beyond Progression (All Drivers- RET, MET, EGFR, etc.)
15:50 - 16:50 EST	Targeted Therapies KRAS View Presentations Sotorasib Mirati – (Adagrasib?) Effect of Co-Mutations Combinations
17:00 - 18:00 EST	Targeted Therapies All the Others View Presentations MET RET BRAF HER2, NRG Fusions, NTRK
18:10 - 19:10 EST	Industry Symposium

13:30 - 14:30 EST	Immunotherapy
14:40 - 15:40 EST	IO Biomarkers View Presentations TMB and Other Neoantigen Quanitification Methods Statistical Models Multi-fluorescence, TME Blood Based Biomarkers
15:50 - 16:50 EST	IO Other Immunologic View Presentations Personalized Cancer Vaccines Cellular Therapies, Adoptive T-cells Intratumoral Injections, TILs Aiming the Immune System at Mutation-driven Tumors
17:00 - 18:00 EST	Antibody Drug Conjugates View Presentations Pharmacology, Toxicity ADC for HER 2, HER3 incl Trastuzimab Ematansine and Dexretuxin, DS8021, U31402 ADC for Trop 2 incl DS1062, Immuno 132 Other ADCs
18:10 - 19:10 EST	Industry Symposium

09:00 - 10:00 EST	SCLC View Presentations Chemotherapy + IO Emerging Novel Agents (Lurbinectedin, PARPi, Irinotecan Liposome, APG-1252) Emerging Immunotherapy Approaches (AMG 757, GD-2 CAR & others) New Therapeutic Targets for SCLC Radiotherapy Issues in SCLC
10:10 - 11:10 EST	Best Fellows Oral Talk
11:20 - 12:20 EST	Stage III Unresectable View Presentations PACIFIC Trials Other IO Agents (Besides Durvalumab) & Combinations Ongoing Key Stage III Trials in the NCTN and Beyond Innovations in Radiotherapy Nasser Hanna as backup if Dr. Bezjak is not available
12:30 - 13:30 EST	Therapy for Early Stage View Presentations Neoadjuvant Immunotherapy and Chemotherapy Plus Immunotherapy with Adjuvant Immunotherapy: Phase 2 Results Including Safety and Ongoing Trial Design Adjuvant Immunotherapy and Chemo-Immunotherapy: Phase 2 Results and Ongoing Trials Neoadjuvant and Adjuvant TKI Therapy Trials Results, NGS Testing and Safety Pathologic Response Evaluation
13:30 - 14:00 EST	Closing - Faculty Keynote

© 2021 International Association for the Study of Lung Cancer – IASLC TTLC 2021 | Privacy Notice

Conference Newsletter

Subscribe to the Newsletter to receive important information about the upcoming Meeting.

Whoops, looks like there was an issue with one of the fields above - please review above.

X